Introduction
Chromosome mosaicism is defined as the presence of one or more cell populations with different genotypes in some of the body's cells in the same individual. Chromosomal mosaicism has been implicated as a leading genetic cause of human prenatal death, early prenatal brain development, congenital malformations, and many human diseases. [1] [2] [3] Several renowned mosaic chromosome syndromes include genetic disease such as Pallister-Killian syndrome (tetrasomy 12p mosaicism [PKS, OMIM 601803]), Hypermelanosis of Ito (HMI, OMIM 300337) and milder versions of known diseases (e.g., mosaic Down syndrome and mosaic Klinefelter syndrome). 4) Mosaic trisomy 14 syndrome is a well-known but unusual chromosomal abnormality with a distinct and recognizable phenotype. [5] [6] [7] [8] [9] [10] The clinical features include retarded growth
Clinical Findings
A 6.4-year-old girl was referred to the clinical genetics clinic for evaluation of short stature, dysmorphic features and developmental delay. She was born at 41 weeks of gestational age by spontaneous vaginal delivery after an unremarkable pregnancy. She was the first child of non-consanguineous Korean parents: a 28-year-old healthy mother and a 29-year-old healthy father. Her birth weight was 3,220 g [-0.05, standard deviation (SD) 13) ]. She had a healthy younger brother. The family history was negative for stillbirths, infant deaths, birth defects, developmental delays and genetic disorders.
At birth, she showed clubfeet. Her parents reported that she had poor sucking power, feeding difficulty, and poor weight gain during her first year of life. She underwent ligation of the patent ductus arteriosus (PDA) at 8 months of age.
She showed apparent global development delay from early infancy. She held her head at 4-5 months, walked independently at 27 months, and used one word with meaning at 15 months. She exhibited apparent language disability: she made short sentences with two words at the age of 6.4 years. There was no history of seizure.
When she initially visited our clinic as a 6.4-year-old, she exhibited short stature: her height was 101.4 cm (-3.4 SD), body weight was 18.2 kg (-1.2, SD), body mass index (BMI) was 17.7 kg/m 2 (-1.6 SD), and head circumference was 51. 1 cm (+0.2 SD). On examination, she had round shaped face, broad upturned nose, depressed nasal bridge, large mouth, widely spaced teeth, and short neck (Fig. 1) . She presented multiple hyperpigmented patches on her whole body, especially on the upper and lower extremities. Musculoskeletal and neurological examinations were normal. A metabolic screening test by tandem mass spectrometry (MS) was normal. All other laboratory tests, including complete blood count, chemistry panel, thyroid function test, and urinalysis were normal. Radiologic exam revealed no evidence of abnormalities. Insulin like growth factor (IGF-1) was 714 ng/ml (normal range for age, 48.5-214 ng/ml) and insulin like growth factor binding protein 3 (IGFBP-3) was 3.23 mg/L (normal range for age, 1.5-3.4 mg/L). Bone age was retarded for the chronologic age: estimated bone age was 4.5-5 years at her age of 6.4 years.
Array CGH Analysis and Chromosome analysis
We conducted a whole genome array comparative genomic hybridization (array CGH) using commercially available array CGH slides (MACArray Karyo 1440 BAC-chip, Macrogen, Seoul, Korea). The array CGH chip data were analyzed using a chromofluor image analysis system (Macrogen, Seoul, Korea). Test to reference ratios were automatically determined for each sample and the means reported as a log 2 Test/Reference (T/R ratio) signal ratio graph. An average log 2 T/R signal ratio value more than +0.250 (2.5 SD) was considered as a chromosome number gain, whereas an average log 2 T/R signal ratio value less than -0.250 (2.5 SD) was classified as a chromosome number loss.
Array CGH analysis indicated that all log 2 T/R ratios were within ±2.5 SD (Fig. 2) . The spot of chromosome 14 was also within log 2 T/ R ratio 0.250, but it was slightly increased to 0. 124 when compared with the other chromosomes (Fig. 2) . We conducted G band standard karyotyping, considering a possibility of low-level copy number changes in chromosome 14. Chromosome analysis was conducted on 30 G-banded metaphase cells from peripheral blood T-lymphocytes according to routine cytogenetic protocols. The G-banding analysis revealed mosaic trisomy 14 ( Fig. 3) : 47, XX, +14 [7] /46, XX [23] . Thus, the percent aneuploidy on karyotyping was 23.3%. clinical features compared with previous Korean case, including broad nasal bridge, anteverted nose, and wide lip, abnormal skin hyperpigmentation, failure to thrive, and delayed development. Mosaicism aneuploidy arises from mitosis or meiosis. Co-occurrence of mosaic trisomy and uniparental disomy (UPD) was reported in some case. 16, 17) Up to date, the UPD has been described in association with mosaic trisomy 14 in only one patient with supernumerary marker chromosome 14. 18) Therefore, short tandem repeat (STR) marker study to rule out the possibility of coexist with UPD would be necessary in our case. As we know, array CGH has several advantages over G-banded karyotyping. Array CGH is a non-culture cell based technique and does not need dividing cells. Therefore, turnaround time can be reduced to usually a few hours. Array CGH also shows higher resolution than G-banded karyotyping and enables the detection of submicroscopic chromosomal segment gains and losses.
11) How ever, array CGH cannot detect balanced structural rearrangements such as translocation and inversion, changes in DNA sequences, or gains and losses in regions of the genome not covered by the array CGH. 11) Low proportion mosaicism is also not detected by array CGH. The ability of array CGH to detect low-level mosaicism is not precisely known. Based on a literature review, array CGH is unable to detect a frequency of abnormal cell mosaicism below 20-30%. 12) However, some reports are published that array CGH is more feasible to diagnose low level mosaicism than traditional karyotyping. Ballif et al. 19) analyzed over 3,600 clinical cases. They found out 18 cases of mosaicism. Fourteen cases of 18 were not known at initial analysis by karyotyping and were detected by only array CGH. In all cases, confirmatory fluorescence in situ hybridization (FISH) analyses were performed on phytohemagglutinin (PHA)-stimulated cells and on un-stimulated cultures. They documented that that array CGH can detect the mosaicism as low as 10-20% and find even the missed by previous karyotyping. They also suggested that array CGH based on genomic DNA extracted from uncultured peripheral blood may more precisely detecting the true level of mosaicism than karyotyping based on selectively cultured T lymphocytes. 19) Several reports reveal that G-banded karyotyping may underestimate the level of aneuploidy. 3, 4, 19) Although estimated mosaicism proportion (18.0%) by array CGH was lower than by karyotyping (23.3%) in this study, direct comparison between percent aneuploidy by karyotype using cultured cells and by array CGH using uncultured cell should be interpreted cautiously. Because we only detected counted aneuploidy 14 on PHAstimulated cultured T-cells. Therefore further study estimating aneuploidy 14 on uncultured cell, such as FISH on uncultured blood smear, is warranted. At present, array CGH is clearly viewed as a useful diagnostic tool for detecting copy number changes. However, array CGH can miss low-level mosaicism based on usual cut-off levels. Consequently, the results of array CGH should be interpreted with caution. Traditional karyotyping with cultured T-lymphocytes is still the most commonly used diagnostic method for chromosome mosaicism. We suggest that array CGH is still required to reinforce the information obtained with karyotyping, especially for clinically suspicious patients.
